• 1
    Chatal JF. Radioimmunotherapy, a new breakthrough in the treatment of follicular non-Hodgkin's lymphoma: the European perspective. Cancer Biother Radiopharm. 2006; 21: 1-4.
  • 2
    Juweid M. Radioimmunotherapy of B-cell non-hodgkin's lymphoma: from clinical trials to clinical practice. J Nucl Med. 2002; 43: 1507-1529.
  • 3
    Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med. 2002; 5: 693-713.
  • 4
    Goldenberg DM, Sharkey RM. Advances in cancer therapy with radiolabeled monoclonal antibodies. Q J Nucl Med Mol Imaging. 2006; 50: 248-264.
  • 5
    Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol. 2006; 24: 823-834.
  • 6
    Barbet J, Kraeber-Bodere F, Vuillez JP, Gautherot E, Rouvier E, Chatal JF. Pretargeting with the affinity enhancement system for radioimmunotherapy. Cancer Biother Radiopharm. 1999; 14: 153-166.
  • 7
    Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285: 1182-1186.
  • 8
    Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995; 1: 27-31.
  • 9
    Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma. N Engl J Med. 1991; 324: 1-8.
  • 10
    Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993; 143: 401-409.
  • 11
    Heimann R, Ferguson D, Powers C, Recant WM, Weichselbaum RR, Hellman S. Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer. J Natl Cancer Inst. 1996; 88: 1764-1769.
  • 12
    Garcia-Barros M, Paris F, Cordon-Cardo C, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science. 2003; 300: 1155-1159.
  • 13
    Ishikawa N, Hamada S. Association of medullary carcinoma of the thyroid with carcinoembryonic antigen. Br J Cancer. 1976; 34: 111-115.
  • 14
    Kraeber-Bodere F, Faivre-Chauvet A, Sai-Maurel C, et al. Comparative toxicity and efficacy of 1- and 2-step (bipecific antibody and bivalent hapten) radioimmunotherapy in CEA-producing medullary thyroid cancer. J Nucl Med. 1999; 40: 198-204.
  • 15
    Kraeber-Bodere F, Faivre-Chauvet, A, Sai-Maurel, C, et al. Toxicity and efficacy of radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft: comparison of iodine-131-labeled F(ab”)2 and pretargeted bivalent hapten, and evaluation of repeated injections. Clin Cancer Res. 1999; 5: 3183s-3189s.
  • 16
    Kraeber-Bodere F, Bardet S, Hoefnagel CA, et al. Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine-131-labeled bivalent hapten: Preliminary results of a phase I/II clinical trial. Clin Cancer Res. 1999; 5: 3190s-3198s.
  • 17
    Chatal JF, Campion L, Kraeber-Bodere F, et al. Survival improvement in medullary thyroid carcinoma patients given pretargeted CEA radioimmunotherapy. J Clin Oncol. 2006; 24: 1705-1711.
  • 18
    Kraeber-Bodere F, Sai-Maurel C, Campion L, et al. Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft. Mol Cancer Ther. 2002; 14: 267-274.
  • 19
    Kulke M, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol. 2006; 24: 401-406.
  • 20
    Farker PJ, Speck JC. Protein and cell membrane iodination with a springly soluble chloramine; 1,3,4,6 tetrachloro-3a, 6a-diphenyl glycoluryl. Biophys Res Commun. 1978; 80: 849-854.
  • 21
    Yabu T, Tomimoto H, Taguchi Y, Yamaoka S, Igarashi Y, Okazaki T. Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate. Blood. 2005; 106: 125-134.
  • 22
    Terris B, Scoazec JY, Rubbia L, et al. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology. 1998; 32: 133-138.
  • 23
    Kulke M, Lenz H, Meropol N, et al. A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETS) [abstract]. J Clin Oncol. 2005; 23( suppl). Abstract 4008.
  • 24
    Yao J, Ng C, Hoff P, et al. Improved progression free survival (PFS) and rapid, sustained decrease in tumor perfusion among patients with advanced carcinoid treated with bevacizumab [abstract]. J Clin Oncol. 2005; 23( suppl). Abstract 4007.
  • 25
    Xu Y, Ellison C, Martin E, et al. A phase II study of thalidomide in metastatic neuroendocrine tumors [abstract]. Proc Am Soc Clin Oncol. 2002; 20( suppl). Abstract 1931.
  • 26
    Fontanini G, Vignati S, Pacini F, Pollina L, Basolo F. Microvessel count: an indicator of poor outcome in medullary thyroid carcinoma but not in other types of thyroid carcinoma. Mod Pathol. 1996; 9: 636-641.
  • 27
    Herbst RS, Heymach JV, O'Reilly MS, Onn A, Ryan AJ. Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs. 2007; 16: 239-249.
  • 28
    Kinuya S, Kawashima A, Yokoyama K, et al. Cooperative effect of radioimmunotherapy and antiangiogenic therapy with thalidomide in human cancer xenografts. J Nucl Med. 2002; 43: 1084-1089.
  • 29
    Li XF, Kinuya S, Yokoyama K, et al. Benefits of combined radioimmunotherapy and antiangiogenic therapy in a liver metastasis model of human colon cancer cells. Eur J Nucl Med Mol Imaging. 2002; 12: 1669-1674.
  • 30
    Kinuya S, Yokoyama K, Koshida K, et al. Improved survival of mice bearing liver metastases of colon cancer cells treated with a combination of radioimmunotherapy and antiangiogenic therapy. Eur J Nucl Med Mol Imaging. 2004; 31: 981-985.
  • 31
    Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S, DeNardo GL. Cilengitide targeting of alpha (v) beta integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res. 2002; 62: 4263-4272.
  • 32
    DeNardo SJ, Kroger LA, Lamborn KR, et al. Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma. Cancer. 1997; 80: 2583-2590.
  • 33
    Kraeber-Bodere F, Sai-Maurel C, Faivre-Chauvet A, et al. Toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in mouse model of medullary thyroid carcinoma [abstract]. J Nucl Med. 2005; 46: 145P.
  • 34
    Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 2004; 6: 553-563.
  • 35
    Wachsberger P, Burd R, Dicker AP. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res. 2003; 9: 1957-1971.